Safety of Romosozumab in Osteoporotic Men and Postmenopausal Woman: A Meta-Analysis and Systematic Review.

In conclusion, Romosozumab may have lower adverse effects compared to alendronate and comparable to a placebo, except injection site reactions. Injection site reactions were more with romosozumab compared to alendronate and compared to the placebo as well. Romosozumab appears to have a similar safety profile to bisphosphonates. PMID: 32195618 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32195618?dopt=Abstract

Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - March 21, 2020 Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research